The present invention relates in essence to a compound which decreases or inhibits the binding of mammalian T-cells to mammalian endothelial cells for use in a method of prophylaxis and/or amelioration and/or treatment of clinical adverse events caused by therapy which comprises re-directing of T-cells against target cells in a patient. Methods of treatment of patients having or being at risk of clinical adverse events caused by therapy which comprises re-directing of T-cells against target cells are also contemplated.本發明本質上係關於一種減少或抑制哺乳動物T細胞與哺乳動物內皮細胞結合之化合物，其係用於預防及/或改善及/或治療包含針對患者之標靶細胞重導向T細胞的療法所導致臨床不良事件之方法中。亦涵蓋治療具有或有風險具有包含針對標靶細胞重導向T細胞之療法所導致臨床不良事件的患者之方法。
